Kelly et al. [41] have discovered and performed in vivo pharmacological characterization of potent, highly selective, and bioavailable thienopyrimidine class of IRAK4 inhibitors to treat autoimmune diseases and B cell malignancies. The gene discussed is IRAK4; the disease is autoimmune disease.